Solventum (SOLV) Expected to Release Quarterly Earnings on Wednesday

Solventum (NYSE:SOLV) will likely be announcing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Solventum to post earnings of $1.90 per share and revenue of $2.1540 billion for the quarter. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.13. The business had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same quarter last year, the business earned $1.34 earnings per share. On average, analysts expect Solventum to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Solventum Stock Up 0.3%

SOLV stock opened at $85.69 on Monday. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. Solventum has a fifty-two week low of $62.38 and a fifty-two week high of $88.65. The business has a 50-day moving average of $78.41 and a 200-day moving average of $74.20. The stock has a market capitalization of $14.84 billion, a P/E ratio of 10.50, a P/E/G ratio of 1.32 and a beta of 0.66.

Institutional Trading of Solventum

Several institutional investors and hedge funds have recently modified their holdings of SOLV. Measured Wealth Private Client Group LLC purchased a new stake in shares of Solventum during the third quarter valued at approximately $25,000. CrossGen Wealth LLC purchased a new stake in Solventum in the fourth quarter worth about $25,000. CYBER HORNET ETFs LLC purchased a new stake in shares of Solventum in the 2nd quarter worth approximately $28,000. MUFG Securities EMEA plc bought a new position in Solventum in the 2nd quarter worth about $31,000. Finally, Triumph Capital Management bought a new stake in shares of Solventum during the third quarter valued at approximately $33,000.

Analysts Set New Price Targets

SOLV has been the subject of several research analyst reports. BTIG Research reiterated a “buy” rating and set a $91.00 target price on shares of Solventum in a research note on Monday, July 13th. KeyCorp upped their price objective on Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Weiss Ratings raised shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, July 17th. BMO Capital Markets assumed coverage on Solventum in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price target for the company. Finally, Wedbush began coverage on Solventum in a research note on Friday, May 15th. They set an “outperform” rating and a $94.00 price target on the stock. Seven analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $86.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.